Citation:Yang YH, Kuo HH, Hsu WC, Hsieh YT. Ocular hypertension and severe intraocular pressure elevation after posterior subtenon injection of triamcinolone acetonide for various diseases. Int J Ophthalmol 2020;13(6):946-951,doi:10.18240/ijo.2020.06.14
Ocular hypertension and severe intraocular pressure elevation after posterior subtenon injection of triamcinolone acetonide for various diseases
Received:June 09, 2019  Revised:August 18, 2019
Email this Article  Add to Favorites  Print
DOI:10.18240/ijo.2020.06.14
Key Words:intraocular pressure  ocular hypertension  uveitis  retinal vein occlusion  triamcinolone acetonide
Fund Project:
           
AuthorInstitution
Yun-Hsiang Yang Department of Ophthalmology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei 231, Taiwan, China
Hua-Hsuan Kuo Department of Ophthalmology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei 231, Taiwan, China
Wei-Cherng Hsu Department of Ophthalmology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei 231, Taiwan, China; School of Medicine, Tzu Chi University, Hualien 970, Taiwan, China
Yi-Ting Hsieh Department of Ophthalmology, National Taiwan University Hospital, Taipei 10002, Taiwan, China
Hits: 118
Download times: 19
Abstract:
      AIM: To evaluate and compare the incidences of ocular hypertension and severe intraocular pressure (IOP) elevation after posterior subtenon injection of triamcinolone acetonide (PSTA) for various diseases.

    METHODS: Totally 179 eyes that had received PSTA for diabetic macular edema (n=108), pseudophakic cystoid macular edema (n=20), branch retinal vein occlusion (n=16), central retinal vein occlusion (CRVO, n=14), choroidal neovascularization (n=14) or noninfectious uveitis (n=7) were retrospectively enrolled. The primary outcomes included ocular hypertension defined as an IOP>21 mm Hg, and severe IOP elevation defined as a rise of 10 mm Hg or more in IOP compared with baseline. Cox regression models were used to analyze the hazard ratios (HRs) among different diseases.

    RESULTS: After PSTA, the mean IOPs from month 1 to month 6 all significantly increased (P<0.05). Ocular hypertension occurred in 30.7% of eyes (median time: 8wk), and severe IOP elevation occurred in 16.2% of eyes (median time: 9wk). Patients receiving PSTA for CRVO or uveitis had a significantly higher risk for ocular hypertension (HR=3.049, P=0.004 for CRVO; HR=5.464, P=0.019 for uveitis) and severe IOP elevation (HR=2.913, P=0.034 for CRVO; HR=7.650, P=0.009 for uveitis).

    CONCLUSION: IOP significantly increases within 6mo after PSTA, with the onset of ocular hypertension happening mostly at 2 to 3mo. Patients of CRVO or noninfectious uveitis have a higher risk of ocular hypertension or severe IOP elevation after PSTA and should be monitored for IOP more carefully.

PMC FullText Html:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270252/
Supplementary Material
PDF Fulltext  Download reader  HTML Fulltext   View/Add Comment